Luteinizing hormone-releasing hormone antagonists

Mezö, Gábor; Manea, Marilena

Luteinizing hormone-releasing hormone antagonists

Files

Mezo_EOTP_2009.pdf(328.88 KB)

Date

2009

Authors

Mezö, Gábor

Manea, Marilena

Publication type

Journal article

Published in

Expert Opinion On Therapeutics Patents ; 19 (2009), 12. - pp. 1771-1785. - ISSN 1354-3776. - eISSN 1744-7674

Abstract

Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity. Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications.
Objective/method: Here we give an overview of the most relevant LH-RH antagonists and their therapeutic applications. Recently patented compounds as well as drug formulations and dosage are presented.
Conclusion: LH-RH antagonists have found clinical applications in in vitro fertilization, benign prostatic hyperplasia, endometriosis and in the treatment of hormone-dependent tumors. Work in progress is focused on further development of both peptidic and orally active non-peptidic LH-RH antagonists.

Subject (DDC)

540 Chemistry

Cite This

ISO 690

MEZÖ, Gábor, Marilena MANEA, 2009. Luteinizing hormone-releasing hormone antagonists. In: Expert Opinion On Therapeutics Patents. 19(12), pp. 1771-1785. ISSN 1354-3776. eISSN 1744-7674. Available under: doi: 10.1517/13543770903410237

BibTex

@article{Mezo2009Lutei-9668,
  year={2009},
  doi={10.1517/13543770903410237},
  title={Luteinizing hormone-releasing hormone antagonists},
  number={12},
  volume={19},
  issn={1354-3776},
  journal={Expert Opinion On Therapeutics Patents},
  pages={1771--1785},
  author={Mezö, Gábor and Manea, Marilena}
}

RDF

<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/9668">
    <dc:contributor>Manea, Marilena</dc:contributor>
    <dcterms:title>Luteinizing hormone-releasing hormone antagonists</dcterms:title>
    <dc:language>eng</dc:language>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/9668/1/Mezo_EOTP_2009.pdf"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-24T18:13:34Z</dc:date>
    <dc:format>application/pdf</dc:format>
    <dcterms:issued>2009</dcterms:issued>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/52"/>
    <dc:creator>Mezö, Gábor</dc:creator>
    <dc:creator>Manea, Marilena</dc:creator>
    <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/9668"/>
    <dc:rights>terms-of-use</dc:rights>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/9668/1/Mezo_EOTP_2009.pdf"/>
    <dcterms:bibliographicCitation>First publ. in: Expert Opinion On Therapeutics Patents ; 19 (2009), 12. - S. 1771-1785</dcterms:bibliographicCitation>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dcterms:abstract xml:lang="eng">Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity. Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications.&lt;br /&gt;Objective/method: Here we give an overview of the most relevant LH-RH antagonists and their therapeutic applications. Recently patented compounds as well as drug formulations and dosage are presented.&lt;br /&gt;Conclusion: LH-RH antagonists have found clinical applications in in vitro fertilization, benign prostatic hyperplasia, endometriosis and in the treatment of hormone-dependent tumors. Work in progress is focused on further development of both peptidic and orally active non-peptidic LH-RH antagonists.</dcterms:abstract>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/52"/>
    <dc:contributor>Mezö, Gábor</dc:contributor>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
  </rdf:Description>
</rdf:RDF>

Bibliography of Konstanz

Yes